Statement attributable to:
Bobby Mukkamala, MD
President, American Medical Association
“Reducing the cost and leveraging the scale of Medicare and Medicaid to boost access to game-changing weight loss drugs is a transformative step in the battle against chronic disease and obesity. The American Medical Association (AMA) applauds the Trump Administration for its leadership in making these breakthrough drugs more affordable and accessible to our patients—a key priority for the AMA.
“Obesity is a complex disease that requires evidence-based treatment. Expanding access to effective therapies such as GLP-1 medications represents a significant step forward in confronting an obesity epidemic that now affects more than 40 percent of adults in the United States. These medications not only support weight loss but have also proven effective in reducing the risk of type 2 diabetes, cardiovascular disease, stroke, and other chronic conditions.
“The AMA also encourages private insurers to expand coverage for obesity treatment in alignment with these policy changes. The AMA strongly supports coverage policies that treat obesity with the urgency, compassion, and scientific rigor it deserves.”
Media Contact
About the American Medical Association
The American Medical Association is the physicians’ powerful ally in patient care. As the only medical association that convenes 190+ state and specialty medical societies and other critical stakeholders, the AMA represents physicians with a unified voice to all key players in health care. The AMA leverages its strength by removing the obstacles that interfere with patient care, leading the charge to prevent chronic disease and confront public health crises and, driving the future of medicine to tackle the biggest challenges in health care.
